Loading...
Boston Scientific Corporation
BSX•NYSE
HealthcareMedical - Devices
$102.03
$-0.80(-0.77%)
Boston Scientific Corporation (BSX) Financial Performance & Statements
Review Boston Scientific Corporation’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
17.61%
↑ 17.61%
Operating Income Growth
11.10%
↑ 11.10%
Net Income Growth
16.32%
↑ 16.32%
Operating Cash Flow Growth
37.24%
↑ 37.24%
Operating Margin
17.52%
↑ 17.52%
Gross Margin
67.15%
↑ 67.15%
Net Profit Margin
11.58%
↑ 11.58%
ROE
9.56%
↑ 9.56%
ROIC
8.77%
↑ 8.77%
Boston Scientific Corporation (BSX) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Boston Scientific Corporation stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $4.56B | $4.21B | $4.12B | $3.86B |
| Cost of Revenue | $1.47B | $1.31B | $1.53B | $1.21B |
| Gross Profit | $3.10B | $2.90B | $2.58B | $2.65B |
| Gross Profit Ratio | $0.68 | $0.69 | $0.63 | $0.69 |
| R&D Expenses | $459.00M | $407.00M | $383.00M | $366.00M |
| SG&A Expenses | $1.61B | $1.56B | $1.45B | $1.36B |
| Operating Expenses | $2.42B | $2.16B | $1.84B | $1.95B |
| Total Costs & Expenses | $3.89B | $3.48B | $3.37B | $3.16B |
| Interest Income | $107.00M | $0.00 | $0.00 | $0.00 |
| Interest Expense | $80.00M | $79.00M | $77.00M | $69.00M |
| Depreciation & Amortization | $348.00M | $306.00M | $311.00M | $304.00M |
| EBITDA | $1.01B | $1.05B | $812.00M | $984.00M |
| EBITDA Ratio | $0.22 | $0.25 | $0.20 | $0.26 |
| Operating Income | $675.00M | $733.00M | $747.00M | $693.00M |
| Operating Income Ratio | $0.15 | $0.17 | $0.18 | $0.18 |
| Other Income/Expenses (Net) | -$90.00M | -$64.00M | -$100.00M | -$67.00M |
| Income Before Tax | $585.00M | $669.00M | $420.00M | $608.00M |
| Income Before Tax Ratio | $0.13 | $0.16 | $0.10 | $0.16 |
| Income Tax Expense | $23.00M | $200.00M | $98.00M | $115.00M |
| Net Income | $566.00M | $468.00M | $324.00M | $492.00M |
| Net Income Ratio | $0.12 | $0.11 | $0.08 | $0.13 |
| EPS | $0.38 | $0.32 | $0.22 | $0.34 |
| Diluted EPS | $0.38 | $0.32 | $0.22 | $0.33 |
| Weighted Avg Shares Outstanding | $1.47B | $1.47B | $1.47B | $1.47B |
| Weighted Avg Shares Outstanding (Diluted) | $1.49B | $1.49B | $1.48B | $1.48B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan